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EXPERIMENTS ON CHEMICAL ALTERATION 
OF VIRUS INFECTIONS* 
FRANKL. HORSFALL, JR. 
Member, The Rockefeller Institute 
for Medical Research 
New York, New York 
A
SURVEY of the Harvey Lectures of the past 20 years reveals 
that no fewer than 11 of them considered viruses or the 
natural history of infections induced by these agents, but that none 
dwelt on artificial alteration of virus infections. This is readily 
understood for there was not much that could have been told about 
modification of such infections until recently. Although it has 
been known for some time that a variety of substances affect 
viruses in the test tube and that some may affect the course of 
infectious processes induced by these agents, it is only within 
the last few years that systematic studies have been undertaken on 
the effects of chemical substances on virus infections. But now 
substances are available which cause alteration of one or more of 
the infections induced by viruses in animals, plants, or bacteria. 
Some hundreds of papers on the effects of various substances on 
viral agents or infections induced by them have appeared. Refer­
ences to many of these communications may be found in recent 
reviews of this field.1• 2 As is often the case, most information has 
been acquired in those areas in which it has been feasible to obtain 
the most quantitative data. It would be impossible in the brief 
time before us to undertake an appraisal of available data or even 
to summarize adequately the more important communications. 
Many thousands of substances, either of biological origin or 
produced in chemical laboratories, have been tested for inhibitory 
activity against various viruses. The vast majority have been found 
to be devoid of such activity. But a number of substances have 
been discovered to possess some inhibitive capacity in certain viral 
* Lecture delivered November 20, 1952.
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infections. The heterogeneity of these materials is bewildering; 
some are highly complex structures such as polysaccharides3-5 or 
proteins; 6 others are relatively simple structures such as acridines1-9 
or analogs of amino acids.1 0, 11 In most instances little attention has 
been directed to the mechanism of action of the inhibitory sub­
stance. In only a few cases has the site or mode of action been 
intensively studied. 
For purposes of this lecture, it seems desirable to select certain 
illustrative examples which have been subjected to extended study 
and of which we have some personal knoyVledge. The major 
portion of the investigations to be considered this evening were 
carried out by Dr. Harold S. Ginsberg and by Dr. Igor Tamm, 
with whom it has been my good fortune to be associated during a 
number of years. Both workers have been kind enough to permit 
me to use certain of their unpublished data. 
The studies to be described have dealt with medium- and small­
sized viruses: pneumonia virus of mice, mumps, influenza, and 
Newcastle disease, each of which leads to infection of some 
animal species. Each of the agents utilized reacts with certain 
erythrocytes and causes them to agglutinate. In every case with 
which we have dealt, the virus particle itself is responsible for this 
useful reaction, and the concentration of the agent can be deter­
mined with reasonable precision by means of hemagglutination 
in vitro. The advantages of using such viruses are obvious, espe­
cially when it is necessary to carry out numerous measurements 
in many different experiments. The chemical substances used, 
polysaccharides and derivatives of benzimidazole, have been re­
stricted to those which do not demonstrably react with the viruses 
themselves but do alter infections caused by these agents. One of 
the major objectives of the work has been to define the mechanisms 
through which chemical substances alter infectious processes 
induced by animal viruses. 
Our interest in this problem was aroused by an unexpected 
finding made in 1946.3 When certain bacteria were given to mice 
infected with a virus which leads to fatal pneumonia, there oc­
curred an alteration in the course of the virus infection. Instead 
of dying from pneumonia as was anticipated, animals treated in 
this odd manner recovered. 
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Figure 1 shows in summary the results obtained in the initial 
experiments.3 Mice were inoculated with various dilutions of 
pneumonia virus of mice, termed PVM.12 Two days later they 
were given one intranasal instillation of a nonhemolytic strepto­
coccus, termed MG.13 The experiment was terminated on the 11th 
day when the lungs of all surviving animals were examined. From 



























FIG. 1. Effect of one intranasal instillation of streptococcus MG on the mor­
tality and extent of pneumonia in mice infected 2 days previously with various 
amounts of pneumonia virus of mice (PVM). (From Horsfall and McCarty.3) 
tion in the mortality of treated animals, but also that there oc­
curred a comparable reduction in the extent of pneumonia. In 
animals treated with the bacterium, the virus titration end-point, 
indicated by the triangles, corresponded to a dilution of 2.6 log 
units as compared to 4.2 in controls. Thus, in treated animals, an 
inoculum containing 40 times more virus was required to produce 
effects comparable to those found in controls. 
Streptococcus MG is an encapsulated bacterium which is en­
tirely nonpathogenic in the mouse. It does not multiply in the 
mouse lung nor does it persist there for longer than 14 hours. 
Heat-killed microorganisms are as active against infections caused 
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by the virus as are living bacteria. One. instillation of the bac­
terium is effective if given as early as 2 weeks before, or as late as 
4 days after, inoculation with the virus.3•• 
Cell-free extracts of streptococcus MG are as effective as the 
bacterial bodies themselves. The results of enzyme studies and 
physicochemical observations indicated that the active component 
in such extracts might be a polysaccharide. Experiments showed 
that the purified capsular polysaccharide is active and that only a 
few micrograms per mouse causes modification of the virus in­
fection.3 
In Table 1 is shown the extent of multiplication of PVM m 
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* From Horsfall and McCarty;' Ginsberg et al.;• Ginsberg.17 
t 0.1 mg. per mouse, incranasally. 
t Capsular polysaccharide. 
mice after one intranasal instillation of various polysaccharides. 3, 5 
The concentration of virus in the lung was measured 6 days after 
inoculation of 100 fifty per cent maximum score (MS50) doses.14 
It will be noted that the polysaccharides which restrict multiplica-
tion of the virus to 1 O per cent or less of the control value appear 
to have little else in common. So, too, with other polysaccharides 
which .fail to give definite evidence of inhibitory capacity. The 
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dextran utilized merits comment, for it was synthesized from 
sucrose in vitro by means of a cell-free enzyme.5 The finding that 
such a dextran possesses striking inhibitory activity removes any 
doubt that the active substance is actually polysaccharide in nature. 
Each of the capsular polysaccharides derived from the three 
types of Friedlander bacilli is active, though none is related to 
any other serologically. In contrast, capsular polysaccharide of 
pneumococcus type II is wholly inactive, though it is related 
serologically to that obtained from Friedlander type B.15 Thus, it
appears that the structural configurations responsible for serological 
specificity are not those which cause a polysaccharide to possess 
inhibitory activity relative to infections with PVM. 3,5 
We were fortunate in being able to enlist the enthusiastic col­
laboration of Dr. Walther F. Goebel in these investigations, and 
he was kind enough to prepare and purify most of the polysac­
charides that were studied. The relative ease with which large 
amounts of highly purified Friedlander polysaccharide can be ob­
tained15 and the degree of inhibitory activity of that obtained 
from type B led to the choice of this substance for extended 
studies. 
It was found that the route of administration markedly affects 
inhibitory activity, and only on intranasal instillation of the sub­
stance could a definite effect against PVM be demonstrated. 3 Al­
though quantities of the polysaccharide which inhibit multiplica­
tion of the virus cause no lung lesions in mice, larger quantities 
may do so.16 This raised the possibility that the decrease in viral
multiplication was due simply to some nonspecific local damage 
in the lung. If this were the explanation, it seemed probable that 
other viruses which multiply in the same tissue should be in­
hibited by the substance in a similar manner. 
In Table 2 it is seen that the inhibitory effect is specific for 
PVM and that little or no effect is obtained against influenza A or 
B virus multiplying in the lung of the same host species.3• 5• 17 
Moreover, oxidation with periodic acid almost completely abol­
ishes the pneumotoxic activity of the polysaccharide but has no 
effect on its inhibitory activity.3• 5 • 16 These results make it doubtful 
that nonspecific tissue damage is responsible for the observed 
effects. The fact that the inhibitory activity of a single instillation 
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TABLE 2 
EFFECT OF FRIEDLANDER B POLYSACCHARIDE ON MULTIPLICATION 
OF DIFFERENT VIRUSES* 
Virust Host 
Virus Multiplication 
(Per cent of control) 
PVM Mousei 1. 1 
IAV Mousei 63 O 
IBV Mousei 100.0 
* From Horsfall and McCarcy;3 Ginsberg et al.;5 Ginsberg." 
t IAV = influenza A virus; IBV = influenza B virus. 
t 0.1 mg. polysaccharide per mouse, intranasally. 
of the substance persists for 2 or more weeks3 is correlated with 
the fact that the polysaccharide itself persists for very long periods 
in the mouse lung.17 
That the polysaccharide does not react with the virus itself seems 
clear from a number of findings. The substance does not diminish 
infectivity when held with PVM in vitro3 nor does it sediment 
with the virus in high gravitational fields.17 It does not inhibit 
hemagglutination nor diminish adsorption of the virus by either 
RBC or mouse lung tissue.3• 18 That the polysaccharide does not 
block cell receptors is deduced from the fact that the substance 
does not diminish adsorption of the virus by the intact mouse 
lung.s,11 
These findings suggest that the substance is active during the 
multiplication process itself but do not indicate whether the 
effect is on (a) penetration of the cell by the virus, ( b) processes 
related to proliferation of the agent in the cell, or ( c) release of 
newly formed virus particles from the infected cell. 
That Friedlander polysaccharide is a potent inhibitor of multi­
plication of PVM is evident from quantitative studies. Figure 2 
shows the degree of inhibition obtained 6 days after infection 
with 100 MS50 doses of the agent as a function of the quantity of 
polysaccharide given.3 As little as 2 µ,g. given once before inocula­
tion causes over 90 per cent inhibition of multiplication. More 
than 99 per cent inhibition is obtained with any quantity greater 
than 12 µ,g. The degree of inhibition obtained is not a function 
of the technique used to measure viral concentration, and meas-
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urements made by inf ectivity titrations yield results almost 
identical with those secured by hemagglutination in vitro.s,H,, 
In attempting to unrave1 the mechanism of the inhibitory effect, 
it seemed desirable to fragment the infectious process and to ex­
amine each step as closely as feasible. The ideal approach would 
have been to reach down to the cellular level and work with in­
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FIG. 2. Extent of inhibition of multiplication of PVM relative to the amount 
of Friedlander type B capsular polysaccharide given. Concentration of virus in 
mouse lungs was measured 6 days after inoculation with 100 MS .. doses; T =
concentration in treated mice; C = concentration in control mice. (From Hors­
fall and McCarty .3) 
terial viruses. Because this has not as yet been accomplished with 
an animal virus, it was necessary to be content with one-step 
growth experiments.19 , 20 
Like bacterial viruses19 • 21 and influenza viruses, 20, 22 PVM gives 
evidence of multiplying in discrete cycles.23 One of the major 
tenets of modern virology is that a cycle of multiplication is at­
tributable to the series of events which develops as a result of 
infection of individual host cells by individual virus particles. 
Each cycle has four chief parts which evolve in fixed sequence: 
the first is adsorption of virus by host cells; the second is the 
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eclipse or latent period during which the virus disappears; the 
third is the incremental period in which new virus appears in the 
cells and increases in amount; and the fourth is release of newly 
formed virus particles from the infected cells. In each successive 
cycle of multiplication, this sequence of events recurs. 
Thus, the concentration of virus in infected tissue tends to 
increase in stepwise fashion, and each step represents one cycle 
of multiplication of the agent within susceptible cells. The 
PVM 
3.0 
0 8 16 24 .32 
Hou:r:>s 
FIG. 3. Single cycle of multiplication of PVM in the mouse lung. (From 
Ginsberg and Horsfall.23) 
metabolic processes concerned with the development of new virus 
particles operate during the second and third parts of each 
cycle.24-26 Virus multiplication, as such, is confined to the latent 
period and the incremental period. 
As shown in Figure 3, inoculation of mice with a large amount 
of PVM leads to a series of events which has the aspects of a 
single cycle of multiplication. 23 Measurements by both inf ectivity 
and hemagglutination show· that about 10 per cent of the virus 
reaching the lung succeeds in. initiating infection. After inocula­
tion there is a latent period of about 15 hours' duration which is 
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followed by a rise or incremental period of· approximately the 
same length. The complete multiplication cycle requires about 30 
hours, and the yield of virus or step size corresponds to an in­
crement of approximately 16-fold. 
When the polysaccharide is given during the latent period fol­
lowing inoculation with PVM, results such as those shown in 
Figure 4 are obtained.rn No evidence of multiplication appears 
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FIG. 4. Inhibition of multiplication of PVM in the mouse lung when Fried­
lander type B capsular polysaccharide (0.1 mg. per mouse) was given at vari­
ous times during the latent period of a single cycle. The abscissa indicates time 
after inoculation with the virus. (From Ginsberg and Horsfall.1") 
proliferation occurs when the substance is given at 8 or 1 O hours 
after inoculation. However, at 12 hours there is almost no effect 
upon the first cycle of multiplication . 
. Thus, the polysaccharide is inhibitory when given during the 
first two-thirds of the latent period. This finding affords evidence 
that the substance acts during intracellular multiplication and that 
the inhibitory effect is not attributable to prevention of penetration 
of the susceptible cell. In addition; the fact that at 12 hours the 
compound does not diminish the yield of virus from the first cycle 
is indicative that it does not prevent release of virus particles from 
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infected cells. Thus, it appears that the inhibitory effect is due to 
interruption of a process which leads to the development of new 
virus particles. 
When the polysaccharide is given after the latent period, say at 
18 hours, it has no effect upon the yield of virus ·from the first 
cycle of multiplication but prevents proliferation during the next 
cycle.16 The available evidence indicates that the process leading to 
the inhibitory effect on the second cycle is identical with that on 
the first. 
When small inocula are employed, PVM undergoes what ap­
pears to be progressive multiplication.27 The probability is high 
that the apparent logarithmic increase in virus concentration re­
sults from a number of cycles of multiplication which get out of 
phase after the second. After inoculation of 100 MS50 doses, PVM
multiplies throughout a period of 6 days and reaches maximal 
concentration shortly before the animals die. About five cycles of 
multiplication would be expected during this interval. The maxi­
mal yield of virus and the time required to obtain it after inocula­
tion of different quantities of the agent are in accord with this 
view. 
When the polysaccharide is given once after inoculation with 
100 MS00 doses, and the concentration of virus is determined at 
intervals, results like those shown in Figure 5 emerge.3 There is 
little evidence of multiplication even when the substance is given 
as late as 4 days after inoculation. Such findings indicate that the 
polysaccharide can inhibit proliferation of the virus during any 
cycle of multiplication from the first through the fourth or fifth. 
To this point we have been concerned chiefly with evidence in­
dicat_ing that Friedlander polysaccharide acts by interrupting in­
tracellular multiplication of PVM. To inhibit virus proliferation 
is one thing; to restrict the progress of a viral disease may be 
quite another. It will be recalled that in the initial experiments 
with streptococcus MG, treated mice recovered from an infection 
which killed control animals. 3 One may ask: What is the relation 
between the extent of multiplication of a virus and the extent of 
the disease induced? A corollary would be: Does inhibition of 
virus multiplication result in predictable modification of the dis­
ease process? 
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PVM possesses properties well suited to this problem. The ex­
tent of the lung lesions the virus induces is a function of the size 
of the inoculum.27 With large inocula, complete pulmonary con­
solidation develops and mice then die. With small inocula, only 
partial consolidation occurs and animals recover. The amount of 
pneumonia can be estimated with considerable precision and· under 
given conditions is closely reproducible.27• 28 
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FIG. 5. Inhibition of multiplication of PVM in the mouse lung when Fried­
lander type B capsular polysaccharide (0.1 mg. per mouse) was given at vari­
ous times after inoculation of the virus. (From Horsfall and McCarty.3) 
PVM, the virus concentration at the end of a given cycle depends 
upon the amount of virus inoculated. The increment of virus 
from each cycle is constant, but the total yield is a function of the 
number of host cells infected. Without going into the mathe­
matical basis for this conclusion, let us look at the data which 
support it. 27 As shown in Figure 6, a straight line is obtained 
when the logarithm of the virus concentration divided by the 
amount of virus inoculated is plotted against time. The upper line 
depicts both the rate and extent of virus multiplication during 
the first 8 days of the disease. Another straight line is obtained 
when the logarithm of the amount of pneumonia divided by the 
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quantity of virus inoculated is plotted similarly. The lower line 
depicts both the rate of increase and the extent of lung lesions 
during the first 10 days of the disease. 
This evidence indicates that there is a relationship between 
virus concentration and the extent of the disease induced.27•29 Be­
cause the two lines shown have the same intercept at zero time 



















FIG. 6. Relationship between the concentration of PYM in the mouse lung 
and the extent of pneumonia relative to time after inoculatio_n of the virus. 
X = amount of virus or pneumonia per lung; I= amount of virus inoculated. 
(From Horsfall and Ginsberg.27) 
centration and extent of lung lesions during the proliferative 
period and in fact compute one from the other. Tests show that 
computations of the amount of pneumonia expected as a function 
of virus concentration agree with observed values within ± 10 
per cent.21,29 
Because the extent of pneumonia is directly related to the virus 
concentration, it follows that inhibition of multiplication resulting 
in diminished virus concentration should cause restriction in the 
progress of the disease. 
The results of tests of such a therapeutic hypothesis are shown 
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in Figure 7.rn Infected mic� were treated once with 20 µg. of 
Friedlander polysaccharide either on the 2nd or 3rd day after 
inoculation with 100 MS60 doses of PVM. In animals treated on 
the 2nd day, virus multiplication was restricted to 4 per cent and 
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FIG. 7. Results of treatment of mice infected with PVM by Friedlander type 
B capsular polysaccharide ( 0.02 mg. per mouse) either on the 2nd or the 3rd 
day after inoculation of the virus. (From Ginsberg and Horsfall.14) 
recovered, but all controls died by the 7th day. On treatment at the 
3rd day, virus proliferation was held to 12 per cent and lung 
lesions were restricted to 5 5 per cent of that found in controls. 
Two-thirds of the animals treated at this late period recovered. 
The extent to which the development of pneumonia was· restricted 
corresponded, within + 15 per cent, to what was computed from 
the virus concentration found in treated animals. 
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Thus, with PVM, reduction in virus multiplication appears to 
be directly correlated with reduction in the severity of the disease 
induced. When the polysaccharide is given so long after inocula­
tion that virus multiplication has gone through two or three 
cycles23 and the development of pneumonia has begun, the sub­
stance acts as though it were a chemotherapeutic agent and alters 
the course of the infection in favor of the host.3• 16 
Although it is possible to modify a regularly fatal infection 
induced with a small virus in a mammalian host and, with a few 
micrograms of a chemical substance, to change the disease so that 
treated animals recover, this is accomplished under strictly defined 
experimental conditions. Such results are obtained only if the 
compound is given before maximal virus concentration has de­
veloped. If one or more cycles of multiplication remain to be 
completed when the polysaccharide is given, alteration of the in­
fection is attained. But when maximal virus titers have been 
reached, the substance exerts no beneficial effect on the infectious 
process. 3• 16 
Present evidence indicates that the mechanism by which 
Friedlander polysaccharide achieves a therapeutic effect in infec­
tions caused by PVM is through interruption of intracellular virus 
multiplication and that the substance acts only when the prolifera­
tive process is under way but not yet complete. 
Soon after it was found that certain polysaccharides interrupt 
the multiplication of PVM, it was demonstrated that some oCthe 
same substances alter mumps virus infection. 5 In contrast to PVM,
for which the host was the mouse, studies with mumps virus were 
carried out in the chick embryo. 
In· Table 3 is shown the extent of multiplication of mumps 
virus in the allantoic sac after injection of various polysaccharides.5 
The concentration of virus in the allantoic fluid was measured 6 
days after inoculation of 100 fifty per cent embryo infective 
( El50 ) doses. Among the substances examined, only capsular 
polysaccharides from Friedlander bacilli restrict multiplication of 
the agent. It appears clear that serological relationship between 
polysaccharides is not correlated with inhibitory activity relative 
to the mumps agent. As in the case of PVM, the serologically 
unrelated Friedlander polysaccharides are active, while pneu-
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· TABLE 3
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mococcus type II polysaccharide, though related to Friedlander 
type B, 15 is inactive. 
It will be recalled that with PVM evidence for specificity of the 
inhibitory effect was obtained: Compounds inhibitory for PVM 
had no effect on the multiplication of influenza A or B virus.3•5 
With mumps virus, there are further indications of specificity for, 
among 6 polysaccharides with inhibitory activity relative to 
PVM, 3• 5 only 3 show similar activity in infections with mumps 
virus.5 
TABLE 4 
EFFECT OF FRIEDLANDER B POLYSACCHARIDE ON MULTIPLICATION 
OF DIFFERENT VIRUSES* 
Virust Host 
Virus Multiplication 
(Per cent of control) 
Mumps Ch. embryot 0.8 
IAV Ch. embryot 100.0 
IBV Ch. embryot 71.0 
NDV Ch. embryot 100.0 
* From Ginsberg et al.5 
t IAV = influenza A virus; IBV = influenza B virus; NDV = Newcascle disease virus. 
t 0.6 to 1.0 mg. per chick embryo, inrra-allancoically. 
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The data in Table 4 provide additional evidence on thisyoint.5 
Friedlander B polysaccharide, one of the most active in infections 
with either mumps virus or· PVM, has in the chick embryo no 
discernible effect on the multiplication of influehza A, influenza 
B, or Newcastle disease virus. Even when the smallest possible 
inoculum of the latter agents is employed, and polysaccharide is 
given some hours before the virus, multiplication is not inhibited. 
Because Friedlander polysaccharide was used in detailed studies 
on the mechanism of the inhibitory effect with PVM in the mouse, 
the same substance was employed in extended investigations with 
mumps virus in the chick embryo. With the mumps agent, the 
route of administration of the compound proved to be almost as 
crucial as with PVM. Inhibition of virus multiplication is ob­
tained readily if the polysaccharide is injected into the allantoic 
cavity. Similar inhibition occurs also on injection of the substance 
into the yolk sac, but only if the compound is transported to the 
allantoic sac, a transport which occurs in about 50 per cent of 
embryos.5 
The polysaccharide causes no evidence of toxicity· in the chick 
embryo; as much as 10 mg. injected into the allantoic sac does not 
affect the rate of growth or development and does not produce 
demonstrable microscopic lesions in the allantoic membrane or the 
tissues of the embryo.5 These findings, in conjunction with those 
indicative of a specific effect on mumps virus proliferation, sup­
port the idea that the inhibitory effect is not the res1:1lt of some 
nonspecific damage to the allantoic membrane. 
That the polysaccharide does not act on mumps virus itself 
seemed clear from the fact that the compound does not reduce 
infectivity of the virus when held with it in vitro, 5 nor does it in­
hibit hemagglutination by the agent.18 That the polysaccharide 
does not block receptors of the allantoic membrane is evident 
from the fact that mumps virus is• absorbed in a normal manner 
from the allantoic fluid even when the allantoic membrane of the 
living embryo is exposed to 40 mg. of the substance for some 
hours before injection of the agent.18 
The extent of inhibition of mumps virus multiplication ob­
tained with various quantities of the polysaccharide is shown in 
Figure 8.5 Virus concentration was measured 6 days after inocula-
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tion with 100 EI50 doses. As little as 5 p,g. given 3 hours after the 
virus causes more than 90 per cent inhibition of multiplication. 
More than 95 per cent inhibition is obtained with quantities rang­
ing from 50 to 200 p,g. As with PVM,1'6 the degree of inhibition 
is not dependent upon the procedure used to measure virus con­
centration, and infectivity titrations yield results which correspond 
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FIG. 8. Extent of inhibition of multiplication of mumps virus relative to the 
amount of Friedlander type B capsular polysaccharide injected. Concentration of 
virus in allantoic fluids was measured 6 days after inoculation with 100 EJ50 
doses; T = concentration in treated chick embryos; C = concentration in con­
trols. (From Ginsberg et al.5) 
Like PVM, 23 mumps virus also gives evidence of multiplication 
in discrete cycles.30 As shown in Figure 9, inoculation of very 
large amounts of the agent into the allantoic sac results in a series 
of developments which has the features of a single cycle of multi­
plication. There appears to be a latent period of about 24 hours' 
duration which is followed by a rise or incremental period of 8 to 
12 hours. One complete multiplication cycle may require about 
36 hours, and the yield of virus or step size corresponds to an 
increment of approximately 64-fold. 
When the polysaccharide is given during the latent period, say 
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at 3 hours after inoculation with a large amount of mumps virus, 
results different from those obtained with PVM are found.30 The 
yield of virus after the 2nd multiplication cycle at 3 days is only 
10 per cent of that in controls. But after the 4th cycle at 6 days 
the virus concentration is nearly identical with that in controls. 
As shown in Figure 10, the degree of inhibition is affected by 
the quantity of mumps virus injected.5 •30 When 1.0 mg. of the 







FIG. 9. Single cycle of multiplication of mumps virus in the allantoic sac. 
(From Ginsberg and Horsfall.30) 
days, more than 97 per cent inhibition is obtained after inocula 
of 10 to 1,000 El50 doses, but a progressive decrease in inhibition 
develops as more and more virus is given, and after 106 El50 doses 
there is none. 
In seeking an explanation, the possibility of a variant virus 
resistant to the effects of the polysaccharide arose. A number of 
facts pointed in this direction. With small inocula, the polysac­
charide restricts multiplication markedly but does not completely 
interrupt proliferation of the mumps agent. Even relatively large 
amounts of polysaccharide, for example 1.0 mg. per embryo, 
given after small inocula of virus do not entirely prevent mul­
tiplication.5 With large inocula, although multiplication is re-
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stricted by the substance during 2 cycles, maximal proliferation 
of the agent eventually occurs. 30 
The occurrence of a resistant variant of mumps virus is readily 
demonstrable. Serial passage of the agent along with small 
amounts of the polysaccharide, say 50 µ,g., results regularly in the 
emergence of such a variant. Moreover, a single passage with a 
large inoculum in chick embryos given 1.0 mg. of the substance 
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FIG. 10. Extent of inhibition of multiplication of mumps virus by Friedlander 
type B capsular polysaccharide ( 1.0 mg. per chick embryo) relative to the 
amount of virus inoculated. T = concentration of virus in treated chick em­
bryos; C = concentration in controls. (From Ginsberg et al.;" Ginsberg and 
Horsfall.30) 
not permit a reliable determination of the proportion of the re­
sistant variant in the virus population, but a ratio of 1 variant to 
10,000 typical particles would conform with the data.30 
The extent to which the variant is resistant to inhibition by the 
polysaccharide is illustrated in Figure 11.30 The concentration of 
the parent or variant virus was measured 6 days after inoculation 
of 100 EI50 doses in embryos given various quantities of polysac­
charide. Although multiplication of the parent virus is markedly 
inhibited by as little as 50 µ,g., that of the variant is unaffected by 
as much as 1.0 mg. Resistant strains could not be maintained in-
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definitely on passage in the absence of the polysaccharide. After 
numerous serial passages along with the substance, full sensi­
tivity to the inhibitory effect was regained on 5 passages without 
the polysaccharide in normal embryos.
30 
Except for resistance to the effects of the polysaccharide, the 
variant virus possesses no other properties which serve clearly to 
distinguish it from the parent agent. Infectivity, hemagglutinat­
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FIG. 11. Resistance of a variant of mumps virus to inhibition by Friedlander 
type B capsular polysaccharide. T = concentration of virus in treated chick 
embryos; C = concentration in controls. (From Ginsberg and Horsfall.30) 
from those of typical mumps virus. There is, however, evidence 
indicating that the rate of multiplication is slower than that of the 
parent.30 
Segregation of a resistant variant from a virus population by an 
inhibitory chemical substance is formally analogous to selection 
of resistant mutants from bacterial populations by chemo­
therapeutic agents. 31 That the variant can be obtained at will and 
from various strains of the agent is indicative that mumps virus 
populations are not homogeneous and that natural variants in such 
populations possess distinctive properties. Procedures available 
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for the study of animal viruses do not permit rigorous proof that 
the variant is in fact a mutant, but it seems obvious that the find­
ings are not at odds with such a view. 
When small inocula of mumps virus are employed, the mul­
tiplication of the agent appears to be progressive and, as with 
PVM, discrete cycles after the first tend to disappear in a curve of 
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FIG. 12. Inhibition of multiplication of mumps virus in the allantoic sac 
when Friedlander type B capsular polysaccharide ( 1.0 mg. per chick embryo) 
was given at various times after inoculation of the virus. (From Ginsberg 
et al.") 
multiplies in the allantoic sac during a period of 6 days. About 
four cycles of multiplication can be expected in this interval. Both 
the maximum yield of virus and the time required to obtain it 
after inoculation of various _quantities of the agent are in accord 
with this concept. 
When 1.0 mg. of the polysaccharide is given after inoculation 
of 100 EI50 doses and the concentration of virus is measured ·at 
the 6th day, results such as shown in Figure 12 are obtained.5 It 
will be noted that there is only slight evidence of .proliferation 
when the substance is given either on the 1st or the 2nd day after 
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inoculation. Little multiplication of the agent occurs when the 
substance is given on the 3rd day, and, even when it is not given 
until the 4th day, there is de.finite limitation in the degree of 
multiplication. 
These .findings indicate that, despite the potential occurrence 
of a resistant variant, the polysaccharide markedly impedes mul­
tiplication of mumps virus at any time through the 4th day after 
inoculation, as is the case also with PVM. 3 In addition, they 
support the idea that any multiplication cycle from the .first 
through the third or fourth can be inhibited by the substance. 
Infection of the chick embryo with mumps virus is not asso­
ciated constantly with the development of gross lesions and does 
not regularly cause death of the embryo. As a consequence, it is 
not feasible to investigate any effects the polysaccharide may have 
on the mild disease process induced in this species by the agent. 
The fact that the polysaccharide does not affect adsorption of 
mumps virus by the allantoic membrane,18 but does inhibit mul­
tiplication of the agent when given during the latent period,30 
supports the hypothesis that the mechanism of the inhibitory effect 
is closely similar to that postulated for PVM: 3 • 16 that inhibition is 
due to interruption of a process which leads to the development 
of new virus particles. It should be emphasized that, as too with 
PVM,3 the substance does not cause a reduction in the concentra­
tion of preformed virus and an inhibitory effect is demonstrable 
only if the substance is given before maximal virus concentration 
has developed.5 
With both PVM and mumps, attention has been drawn to the 
specificity of the inhibitory action of the polysaccharide. In the 
mouse, the substance has no effect on the multiplication of in­
fluenza A or B virus. 3• 5• 17 In the chick embryo, the compound 
does not alter the proliferation of either of these agents or of 
Newcastle disease virus.5 If, as the evidence suggests, the in­
hibitory action of the polysaccharide is attributable to blocking of 
cellular metabolic systems necessary for virus multiplication, then 
it appears that influenza and Newcastle disease viruses do not 
demand the same metabolic systems that PVM and mumps virus 
need for proliferation. 
One approach to this hypothesis is by means of interference 
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experiments. There is much evidence pointing to the probability 
that interference is dependent on competition between two viruses 
for cellular systems essential to multiplication of the agents.32-H 
If viral interference and chemical inhibition of virus multiplica­
tion are dependent upon similar metabolic mechanisms, then there 
should be a close correlation between the results of the two types 
of experiments with the same agents. 
A summary of evidence indicating that there is such a correla­
tion is shown in Table 5. Interference experiments with two 
TABLE 5 
CORRELATION BETWEEN CHEMICAL INHIBITION OF MULTIPLICATION 
AND INTERFERENCE* 
Effect of Polysaccharidd on Multiplication 
Inhibition of both 
Inhibition of one, not the other 
Inhibition of one, not the other 
Inhibition of one, not the other 
Inhibition of one, not the other 
Inhibition of one, not the other 
No effect on either 
No effect on either 
No effect on either 
No effect on either 
No effect on either 
* From Ginsberg and Horsfall;85 -37 Ginsberg." 
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viruses are of necessity carried out in one host species. Although 
mumps and Newcastle disease viruses do not multiply, in the 
classical sense, in the mouse, it has been demonstrated that both 
agents cause reactions in this species which make it feasible to 
employ them in interference experiments.35• 36 Friedlander polysac­
charide markedly inhibits proliferation of both PVM3• 16 and 
mumps virus.5 Presumably, therefore, these two viruses require 
some of the same metabolic systems for multiplication. From this 
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one may predict that they should show interference, as has been 
demonstrated in fact, in the mouse.35 Although the polysaccharide 
inhibits multiplication of either PVM or mumps virus, it has no 
effect on proliferation of influenza A or B virus either in the 
mouse or the chick embryo.3• 5• 17 As a consequence, it may be as­
sumed that influenza viruses do not require the metabolic systems 
blocked by polysaccharide. If the systems needed by PVM and 
mumps virus are different from those required by influenza 
viruses, it would be expected that PVM and influenza viruses, as 
well as mumps and influenza viruses, should not show inter­
ference. This expectation is borne out by the results of experi­
ments in either the mouse or cµick embryo.37 Influenza and New­
castle disease viruses show reciprocal interference in both host 
species. 36• 38-40 Therefore, these three agents are assumed to utilize 
similar metabolic systems during multiplication. If the require­
ments of these agents are in fact similar, one may anticipate that 
a substance which has no effect on the multiplication of one should 
not affect multiplication of the others. As is indicated, this is 
indeed the case.3• 5 • 17 
This correlation between the results of dissimilar experiments 
with five viruses in two host species does not of itself provide 
direct evidence as to the nature of the mechanisms of virus inter­
ference or chemical inhibition of virus multiplication, but it does 
afford support for the idea that the mechanisms are similar. 
Although much has been learned in these studies on the mech­
anism by which a polysaccharide inhibits the multiplication of two 
animals viruses, there seems to be small likelihood that the investi­
gations can be carried to a point where the mechanism can be de­
scribed in precise biochemical terms. The great difficulties of 
polysaccharide structural chemistry, the uncertainty regarding cell 
systems which might be blocked by these complex substances, and 
the lack of effective antagonists of known constitution have led 
us to undertake studies with other inhibitory substances of pre­
cisely defined structure. 
For studies on the mechanism ,of chemical alteration of virus 
infections, influenza viruses possess certain advantages over PVM 
and mumps virus. Unlike the latter agents, influenza viruses are 
pathogenic for a number of small animal species. In addition, the 
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influenza viruses have relatively short cycles of multiplication,20,22 
they readily and rapidly proliferate in tissue culture systems, and 
their concentration can be measured with considerable precision 
in vitro.41 
In the hope that host cell metabolism might be affected in a 
selective manner and the proliferation of influenza virus restricted 
in consequence, Dr. Igor Tamm initiated and carried forward a 
series of studies with analogs of certain of the B vitamins. When 
it was discovered that some of these compounds did in fact inhibit 
the multiplication of influenza A and B viruses, it became evident 
that an extended investigation was warranted. We were fortunate 
in being able to interest Dr. Karl Folkers, Research Laboratories 
N










FIG. 13. Structure of 5,6-dimethylbenzimidazole (I), adenine (II), and2,5-dimethylbenzimidazole (III). (Courtesy, Yale /. Biol. & Med., 24, 559,1952.) 
of Merck & Company, in this problem. He became a close collabo­
rator and kindly undertook the preparation of a variety of cbm­
pounds. 
Because it seemed probable that an alteration in nucleoprotein 
metabolism would be reflected in an effect upon virus multiplica­
tion, it was decided to concentrate efforts on compounds bearing 
some relation to vitamin B12• This vitamin is known to play an 
important role in nucleoprotein metabolism. That there is a close 
metabolic relationship between vitamin B12 and desoxyribonucleic 
acid is apparent from considerable evidence involving microbial 
growth. 42 The vitamin contains a benzimidazole moiety43 and, 
when it was found that certain substituted benzimidazoles possess 
inhibitory activity relative to influenza virus multiplication,44 a 
detailed study with such compounds was undertaken. 
In Figure 13,45 are shown the structure of 5,6-dimethylbenzi-
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midazole (I), the moiety present in vit_amin B12 ; that of the purine 
adenine (II); as well as that of 2,5-dimethylbenzimidazole (III), 
an analog of the B12 moiety. It will be noted that the purine and 
the two benzimidazole derivatives all possess a bicyclic skeleton 
of the same size and have a common imidazole ring. From this it 
appears that there is a relationship between the structural con­
figuration of adenine, a constituent of nucleic acid, and that of the 
benzimidazole moiety of vitamin B12 , which regulates nucleic 
acid metabolism. As will be demonstrated, both the 5,6-dimethyl 
and the 2,5-dimethyl benzimidazole derivatives are active as in­
hibitors of influenza virus multiplication. 
In order to simplify the virus-host cell system as much as possi­
ble and to make results as reproducible as feasible, portions of 
surviving chorioallantoic membrane were maintained in a chemi­
cally defined medium containing only inorganic salts and glucose.46 
Membranes in this medium were mixed with the virus and shaken 
mechanically at 35° throughout the experimental period. In such a 
system, 2,5-dimethylbenzimidazole inhibits multiplication of in­
fluenza A or B virus. 45 
As illustrated in Figure 14, at a concentration of about 
0.0015 M, the substance 'causes a definite diminution in the yield 
of influenza. B virus.45 The degree of inhibition _increases as the 
concentration of the substance is increased under the fixed experi­
mental conditions. Such a relationship between the concentration 
of benzimidazole derivative and the extent of restriction in virus 
multiplication obtains with all the compounds studied thus 
far. 47-50 This makes it possible to determine with considerable 
precision the quantity of a compound capable of causing inhibition 
of fixed extent. For purposes of comparison, the activity of 
various derivatives is expressed in terms of the molar concentra­
tion capable of causing 75 per cent inhibition of multiplication. 
That the inhibitory effect is not due to direct action of the 
substance on the virus is evident from the following findings: 
The compound does not inactivate the inf ectivity of influenza 
virus when held with it in vitro. Moreover, it does not inhibit 
hemagglutination by the agent and does not diminish adsorption 
of the virus by susceptible host cells. That the inhibitory activity 
of the compound is not attributable to either nonspecific or 
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irreversible effects is indicated by the facts that it does not affect 
the oxygen consumption of the host tissue and that, after pro­
longed exposure to the substance, membranes still retain in 
undiminished degree the capacity to support influenza virus 
multiplication when the concentration of the compound is suf­
ficiently reduced.45 
These findings led to an analysis of the effects of various other 
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FIG. 14. Extent of inhibition of multiplication of influenza B virus in chorio­
allantoic membranes in vitro relative to the concentration of 2,5-dimethylbenz­
imidazole in the medium. (From Tamm et al.'5) 
fluenza viruses. As is shown in Table 6, 47-50 benzimidazole itself 
inhibits the multiplication of influenza B virus. A concentration 
of no more than 0.0035 M causes 75 per cent inhibition in the 
multiplication of the agent. The addition of a methyl group at 
the 2-position in the imidazole ring has, as can be seen, no definite 
effect on the inhibitory activity of the compound. However, the 
addition of such a group at the 5-position in the benzene ring 
yields a substance that is twice as active as the unsubstituted 
compound. The inhibitory activity of the 5,6-dimethyl compound, 
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TABLE 6 
INHIBITION OF INFLUENZA B VIRUS MULTIPLICATION 
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the moiety present in vitamin B12 , is almost identical with that of 
the 5-methyl compound shown in this table. That a substituent 
group at the 2-position does bear on the activity of these deriva­
tives is evident from the results obtained when methyl groups are 
placed at both positions 2 and 5. With the 2,5-dimethyl com-
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TABLE 7
INHIBITION OF INFLUENZA B VIRUS MULTIPLICATION 
BY BENZIMIDAZOLE DERIVATIVES* 
Inhibitory
Activity Inhibitory Relative to Benzimidazole Derivative Cone. t Benzimidazole
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* From Tamm et al. 47-50 
t Concentration yielding 75 per cent inhibition of multiplication. 
pound, inhibitory activity is nearly 3 times greater than that of 
benzimidazole itself. 
As is shown in Table 7,4H0 the addition of further methyl
groups at various positions in the benzene ring leads to a pro­
gressive increase in inhibitory activity when a methyl group is 
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also present at position 2 in the imidazole ring. It is· seen that the 
2,5,6,-trimethyl compound is about 4 times more active than the 
reference compound, unsubstituted benzimidazole. The 2,4,5,6,7-
pentamethyl compound is over 16 times more active as an inhibitor 
than is benzimidazole. In this case, a concentration of only 0.0002 
Mis sufficient to cause 75 per cent inhibition in the multiplication 
of influenza B virus. This concentration is equivalent to 40 p,g. of 
the substance per ml. In addition, if an ethyl rather than a methyl 
group is added at position 2 in the imidazole ring, a single methyl 
substituent in the benzene ring, as at the 5-position, yields a 
highly active compound 19 times more effective than the reference 
substance. To increase further the length of the alkyl chain, as 
with a propyl or butyl substituent at the 2-position, does not add 
to activity. It will be noted that the 2-ethyl 5-methyl compound is 
7 times more active than the 2,5-dimethyl compound, which 
provides additional evidence of the importance of substituents 
at the 2-position in the imidazole ring. 
Inhibition of influenza virus multiplication by derivatives of 
benzimidazole is not dependent upon the procedure used to meas­
ure virus concentration and is as readily demonstrated by infec­
tivity titrations as by hemagglutination in vitro. Inhibition is 
obtained when _an active compound is added early in the latent 
period and can be demonstrated during a single cycle of multipli­
cation. 47• 48 Because such compounds have no demonstrable effect 
upon influenza viruses per se, nor upon their adsorption by host 
cells, it seems probable that their inhibitory effects are the result 
of some mechanism which alters biochemical processes occurring 
during virus multiplication. In the absence of any evidence that 
viruses themselves carry out metabolic activities, the present 
tendency is to ascribe the altered metabolism to the host cell. • 
Whether the metabolic processes involved in the inhibitory effect 
of benzimidazole derivatives are in fact related to nucleoprotein 
synthesis remains to be determined. 
It is clear that the structural configuration of various alkyl 
derivatives of benzimidazole markedly affects their capacity to 
cause inhibition of the multiplication of influenza viruses under 
the experimental conditions employed,41-50 Synthetic compounds 
of precisely known structure may prove to be potent tools of wide 
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usefulness in attempts to unravel some of the problems of virus 
proliferation. 
As was indicated earlier, a major objective of the investigations 
described this evening has been to define the mechanisms through 
which chemical substances alter infectious processes induced by 
animal viruses. It is obvious that this objective has not as yet been 
achieved. However, the efforts expended in pursuing it have not 
been unrewarding, and a considerable amount of new information 
has been acquired during the elusive chase. 
To summarize briefly: From studies on kinetics of inhibition 
there emerges the concept that both the polysaccharides and 
benzimidazole derivatives examined impede virus multiplication 
by affecting processes which occur during the latent period. Such 
processes appear to be metabolic and this leads to the idea that 
they are features of the host cell rather than the proliferating 
virus. Should it be found that a virus in action, that is, a virus 
multiplying in a living host cell, possesses attributes different 
from a virus in vitro, and actively participates in metabolic 
transformations, this hypothesis may require drastic revision. 
That the affected processes are subtle and not such as are 
essential to continued life of the host cell is deduced from the lack 
of demonstrable toxicity of inhibitory substances and the absence 
of an effect on oxidative metabolism by benzimidazole deriva­
tives. Further evidence for the subtle nature of these processes 
stems from the specificity of the inhibitory activity of certain 
substances, particularly the polysaccharides which interrupt the 
multiplication of certain viruses but do not affect that of others 
in the same host tissue. This has led to the hypothesis that some 
viruses require metabolic processes different from those needed 
by others, a concept which is supported by the results of inter­
ference experiments with the same agents. 
That multiplication is itself impeded by the effects of inhibitory 
substances appears from the fact that the yield of newly formed 
virus particles from infected cells is diminished, and the expected 
complement of new virus cannot be found no matter how the 
host cells may be fragmented or extracted. 
Finally, in the case of pneumonia virus of mice, an animal virus 
with dimensions of only 40 m,-,,, it appears that there is a direct 
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relationship between concentration of virus in the lung and the 
objective manifestations of the disease, which is to say the amount 
of pneumonia. With this agent, inhibition of multiplication, under 
strictly defined conditions, results in a predictable diminution in 
the pathological process. This, then, is an instance in which the 
administration of a chemical substance during the course of a 
severe disease modifies the virus infection so that the host recovers. 
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